Business Wire

ESG-CLEAN-ENERGY

13.12.2021 17:52:07 CET | Business Wire | Press release

Share
ESG Clean Energy Signs Letter of Intent with Ethatec GmbH to Use Carbon-Free Power Generation for Ethanol Production

ESG Clean Energy, LLC, developers of net zero, distributed power generation and clean energy manufacturing solutions, announced today it has signed a letter of intent (LOI) with Ethatec GmbH for the use of ESG’s patented CO2-free power generation technology to power its production of ethanol.

Under the LOI, US-based ESG Clean Energy will provide its patented carbon-capture system to enable Ethatec GmbH to produce different products in a sustainable way while preventing tons of carbon dioxide from entering the atmosphere every year.

Ethatec uses a unique process using waste from bakeries and pizza factories (old bread, dough, and other starch-based foods). The method involves first crushing and mixing the raw waste with water before being fed into a hammer mill. The resulting liquid is then mixed with water and enzymes and heated in a multi-stage mashing process to saccharify the starch. It is then cooled and fed into fermentation tanks. Yeast is then added for alcoholic fermentation of the sugar and after 72 hours, the mixture is fed to a distillation system where ethanol is obtained. Ethatec can also produce and manufacture other products using this unique system, including biogas and nitrogen fertilizer.

In order to meet the growing power demand for their production process, significant amounts of energy are required to run the operation. By using the ESG Clean Energy carbon-capture power generation system, Ethatec will be able to use natural gas to power their manufacturing plants while achieving a net zero carbon footprint.

“We are excited to explore the new opportunities with Ethatec and see how our carbon-capture system can augment their unique manufacturing system,” said Lutz Deyerling, Vice President European Operations and Corporate Finance at ESG Clean Energy. “Combining their system with ESG’s carbon-capture technology would create one of the most environmentally friendly systems in the industry today.”

The ESG system is truly unique with its ability to create a Net Zero carbon outcome from a conventional, natural gas, internal combustion engine without loss of efficiency.

Exhaust gas contains a significant amount of water vapor and CO2 as naturally occurring byproducts of the combustion process. By separating those two elements, the ESG system can produce distilled water – and other commodities such as urea, methanol, and recycled plastics – while capturing close to 100% of the CO2.

As a result, Net Zero Carbon Footprint power production is achieved.

Besides electrical power generation, the ESG system can also be utilized in a number of different environments, including:

Plastics Recycling Operations – Can be made more affordable and safer for the environment by providing low-cost, CO2-free heat that is critical to its processing.

Nitrogen Removal – Can be done more efficiently and cleanly. Nitrogen can cause algae blooms in wastewater treatment plants and is a risk to human health, so its removal has become an emerging, worldwide concern.

Stranded Natural Gas Wells – Can be effectively converted from non-operating revenue producers to operating revenue producers by incorporating the ESG system into its production process.

Microgrids – Can be made more reliable in times of emergency with the distributed power abilities of ESG power generation when regional grids go down.

Data Centers – Can provide large data centers with clean low-cost energy in a relatively small package.

Crypto Mining Operations – Can meet the energy demands of crypto mining operations without emitting carbon dioxide into the atmosphere.

For more information about ESG Clean Energy, please visit www.ESGcleanEnergy.com .

About ESG Clean Energy, LLC

ESG Clean Energy, LLC (ESG) develops Net Zero Carbon Footprints and clean energy solutions for businesses and power providers using natural gas. The ESG system utilizes patented, off-the-shelf technology to efficiently produce electricity while capturing and converting 100% of the carbon dioxide and water vapor, which can be used in the production of various commodities, such as distilled water, ethanol, and urea. More information about ESG Clean Energy, its technology, and its current projects can be found at www.ESGcleanEnergy.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye